
Capricor Therapeutics (CAPR) Stock Forecast & Price Target
Capricor Therapeutics (CAPR) Analyst Ratings
Bulls say
Capricor Therapeutics Inc. maintains a strong cash position, which positions the company well for continued operations and development despite regulatory delays. Regulatory feedback indicates that Capricor and the FDA are aligned on the development plan for deramiocel, which is currently in Phase 3 clinical trials for Duchenne muscular dystrophy, suggesting progress toward potential market entry. Additionally, the pending topline data from the HOPE-3 trial, expected in mid-4Q25, combined with positive regulatory discussions, reinforces the company’s favorable outlook and the potential for future product candidates in the exosome space to enhance valuation.
Bears say
Capricor Therapeutics Inc. operates in a challenging environment marked by potential volatility surrounding the upcoming clinical data readouts for its lead product, CAP-1002, specifically from the HOPE-3 trial, which could result in adverse interpretations if the results are negative. The company is facing significant risks related to the success of its clinical trials, as failed or inconclusive results could negatively impact their ability to secure the necessary funding to advance their therapeutics. Furthermore, inconsistencies observed in the secondary and exploratory cardiac-related endpoints raise concerns about the robustness of the clinical findings, further exacerbating the risk profile for investors.
This aggregate rating is based on analysts' research of Capricor Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Capricor Therapeutics (CAPR) Analyst Forecast & Price Prediction
Start investing in Capricor Therapeutics (CAPR)
Order type
Buy in
Order amount
Est. shares
0 shares